Delcath Systems, Inc. (NASDAQ: DCTH), a promising player in the healthcare sector, is capturing investor attention with its potential upside of 134.35%. As a company specialized in medical devices, particularly for treating liver cancers, Delcath presents a unique investment opportunity in the field of interventional oncology.

**Company Overview**

Headquartered in New York, Delcath Systems is dedicated to advancing treatment options for primary and metastatic liver cancers. The company’s flagship product, the HEPZATO KIT, is designed to deliver high-dose chemotherapy directly to the liver, minimizing systemic exposure and associated side effects. This innovative approach is particularly focused on patients with metastatic…